๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS ยท Real-Time Price ยท USD
308.89
-6.93 (-2.19%)
At close: Nov 20, 2026, 4:00 PM EST
308.85
-0.04 (-0.01%)
After-hours: Nov 20, 2026, 7:30 PM EST
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

VYJUVEK demand remains strong, with international launches expected to build through 2027. Key pipeline catalysts include NK enrollment completion by year-end 2027, a mid-2027 CF readout and Hailey-Hailey data in December 2026.

Roger Song
Analyst, Jefferies

Good morning, everyone. Welcome to 2026 Jefferies Global Healthcare Conference. My name is Roger Song, Senior Analyst, cover SMID Cap Biotech in the U.S. It is my great pleasure to have the fireside chat with Krystal Biotech. We have the CEO, Krish Krishnan, and the President R&D, Suma Krishnan. Welcome.

Suma Krishnan
President of Research and Development, Krystal Biotech

Thank you.

Krish Krishnan
CEO, Krystal Biotech

Thanks for having us.

Roger Song
Analyst, Jefferies

Excellent. Krish, why not you start with the state of art of the Krystal? A lot of good things happened in the past, in the entire 2026, and why you are excited about the future, particularly 2027.

Krish Krishnan
CEO, Krystal Biotech

That was going to be a long response.

Roger Song
Analyst, Jefferies

It is okay, keep it short, and then we will have a detailed discussion.

Krish Krishnan
CEO, Krystal Biotech

I will. Look, first, the fundamental business, the commercial business has gone really well. The U.S. launch over the last three years has been really good, but not in terms of patient satisfaction, physician response to the drug. And we started venturing into outside ROW, and we were happy to make a great value proposition of VYJUVEK to patients in Japan. We were very pleased with the outcome of negotiations in Japan. And the same with in Europe. We have a few more countries to do, but we were happy with the value we were able to create for patients and physicians in Germany, and hopefully shortly in Spain and Italy.

Simply said, we feel more confident about the global VYJUVEK launch than we did at the time of the launch, as we learn more about the receptivity of the drug and the nature of the disease in different countries. That is one big aspect. The other aspect of Krystal that we are excited about are all the clinical programs, and we have many readouts upcoming in 2027 that Suma will talk in detail about. And all of these, a lot of them are unmet medical needs, whether it be in CF or VYJUVEK in the eye or NK. And more recently, you saw the data on Gorlin, and we have an upcoming data read on Hailey-Hailey. The skin franchise is getting very strong, and we are expanding into the lung and the eye. And hopefully, we are looking to get started on the aesthetics later in 2027.

The clinical program is good, but surrounding that is an infrastructure of CMC that we spent a lot of time early on in the evolution of the company that helps us get platform technology or whatever that helps support the clinical programs and help us accelerate them through approval. Last but not the least, the financial position of the company is very strong. We have a strong balance sheet. We have been EPS positive for, I can't even remember, eight, nine, 10 quarters, like for a while, only growing very nicely, so much so that we have the confidence that in spite of the R&D investment and looking at the commercial revenue line, we felt good about launching a stock buyback program, which you saw announced in last quarter.

Overall, there's a lot to be excited about, which would not happen without a remarkable team we have at Krystal, not just in the U.S., but worldwide right now.

Roger Song
Analyst, Jefferies

That's a good CEO. You can summarize the whole company within that three minutes for me.

Krish Krishnan
CEO, Krystal Biotech

Yes, there's more to say.

Roger Song
Analyst, Jefferies

Yes. Let's say, talk a little bit more details. You said it very clear, right? Krystal has the very strong commercial business, and also we have a very rich pipeline. Today, we have limited time. Maybe we'll focus on the commercial a little bit more, and also we're going to talk about the key aspects of the pipeline. Okay, so maybe start with VYJUVEK DEB in the commercial business. U.S., I think you added 30 new reimbursement last quarter or third quarter. Would that become the new run rate for 2027 because you're continuing to penetrate? Within that currently active patient, how many of them are actually on drug? Because you have the on and off treatment dynamic.

Krish Krishnan
CEO, Krystal Biotech

Look, I would not take one quarter results as the floor or the steady state going forward.

But it is true after three years of launch. One of the reasons we continue to report reimbursement approvals is to show there is pure demand. We are adding new patients on drug Q over Q over Q. If you look back over the last few quarters, it's been in the range of 30-40, a couple 35s. There's been some good quarters. While I would not take 30 as a floor or this is going to be the future run rate,

we expect somewhere between 30 and 45 to be kind of like looking forward over time.

Roger Song
Analyst, Jefferies

Okay.

Krish Krishnan
CEO, Krystal Biotech

We are going out into the community. We've gotten north of 60% roughly in terms of reimbursement approval market share. Now, it will take us longer to get a patient on drug as we have to reach further out into the community, build awareness, get the physicians to understand genetic medicines, and bring them on drug. So, that part is true.

Now, we announced about, I don't know, north of 760 reimbursement approvals, maybe a bit more.

Patient on drug at a given moment, Roger, is a difficult question-

Roger Song
Analyst, Jefferies

Yeah

Krish Krishnan
CEO, Krystal Biotech

given the start-stop dynamic of the drug. It has been very difficult for us to pinpoint. One indicator we have been looking at since launch has been compliance. Compliance was very high for a long time, and it's definitely on its way down. We're maybe in the 50%-60% in terms of compliance, give or take, and these are moving numbers that vary depending on the disease. But we feel really good about the U.S., both in terms of numbers, but also in terms of patient satisfaction and the outcome, and how much VYJUVEK has improved the lives of so many people in the U.S.

Roger Song
Analyst, Jefferies

Absolutely. By the way, we talk about the compliance. The 50%-60% means those patients are cured literally half of the time during the year. That is why they are stopping using VYJUVEK, because this is a closed wound. If they do not have a wound, they are using the VYJUVEK.

Krish Krishnan
CEO, Krystal Biotech

Look, our number one driver for stopping treatment is wounds are healed.

Roger Song
Analyst, Jefferies

Yeah.

Krish Krishnan
CEO, Krystal Biotech

Without question, right? We have obviously, you have not seen us say anything about safety, because safety to date, knock wood, has been really good on the drug. That is a positive, and that is actually the tail on the drug. If the patient experience is good and they can stop a drug, and we are ready to help them to get back on drug, and we keep this going, that becomes why VYJUVEK is a chronic application for a very long time. We make sure fundamentally, and we have done this since the beginning, that the patient experience on the drug is really good. We have always focused on that, and that served us well.

Roger Song
Analyst, Jefferies

Yep. Awesome. VYJUVEK has been the only approval for DEB for a long time. Recently, we have a cell therapy in a subset of the DEB. How do you think about that launch, and then it is a completely different drug, and then it is kind of grafted, kind of cell therapy. Do you see any impact or any use in your VYJUVEK center, and then when they are using, and then how you think about the VYJUVEK for those patients?

Krish Krishnan
CEO, Krystal Biotech

First and foremost, if you understand the debilitating nature of the disease, as a company in that space, we always welcome alternative treatments to the disease if it were to add a big benefit. The one thing I will say is patients, if you think about VYJUVEK, we have the majority, over 80% of the patients, not only dosing at home, but dosing it by themselves. Because the wound burden is so high. Any of these autologous treatments, whether it is individualized, bespoke, where the patient has to be hospitalized, is in our opinion, burdensome on the patient when there is a simple alternative, easy, at-home administration by the patient or by the parent. Having said that, the wound burden, if you graft a particular wound on a patient, the wound burden on average is 18, 19 wounds in a patient.

There are many other opportunities for Krystal and VYJUVEK to help a patient besides the graft. Cells do turn over, so our view is that at some point, it is not a one-and-done graft on a patient forever. VYJUVEK is always there on a patient, and we are really happy. That said, besides the cell therapy, there are alternative treatments, and we always welcome additional opportunities for the patients, but we feel VYJUVEK has a very strong value proposition in the market.

Roger Song
Analyst, Jefferies

Absolutely. Just to follow up on that, have you treated a patient with that graft, or before and after for the VYJUVEK for such patient? This is a very limited patient, I believe. They have a fixed patient.

Suma Krishnan
President of Research and Development, Krystal Biotech

We do not collect that specific data.

Krish Krishnan
CEO, Krystal Biotech

No. All I will say is, from what I have known, and you cannot pinpoint me to every patient, almost every patient on a graft has been treated with VYJUVEK before across the wounds. Sometimes they get a large wound and the KOL want to try a graft, but

Suma Krishnan
President of Research and Development, Krystal Biotech

They continue to get treated even after the graft.

Krish Krishnan
CEO, Krystal Biotech

Yeah.

Roger Song
Analyst, Jefferies

Okay. Got it. That is good. Then, maybe we will move on to the ex-U.S., because that is another key aspect of the commercial business. It can be as big, if not bigger, than the U.S., which is already trending very high number here. So it is a lot of the pricing, reimbursement dynamic. If you can, just country by country for the initial wave, like Germany, France, Japan, maybe we will focus on those, and then I know that Spain and Italy are coming up. So how is the pricing look like, and then how is the reimbursement? I know you have accrual. Anything you can comment at the higher level, to the degree you can disclose?

Krish Krishnan
CEO, Krystal Biotech

Thank you.

Roger Song
Analyst, Jefferies

Yeah.

Krish Krishnan
CEO, Krystal Biotech

In Germany, we just announced we completed negotiations on pricing on November 1. We have been, prior to that point, we have been on, you can call it expanded access or NPP, whatever term you want to use. While we got the pricing on November 1, we expect Q4 to be not that different than Q3, even though we are starting the launch right now. But definitely having pricing behind us, we are full-blown commercial, we expect the impact to be seen starting in 2027 in Germany. But very pleased with the outcome, very pleased we were able to demonstrate a value proposition, and very pleased that we are able to serve these patients in Germany. I would say in Japan, that has been almost a year. We got pricing maybe like 12, 13 months ago.

In Japan, by law, you have to renew your prescription every two weeks for the first year.

That changes, it actually, the change just happened sometime in November, because it has been one year since launch. So we expect compliance on drug to increase a lot going forward in Japan. The reason I say that is in the first year, a lot of Japanese have to travel long distances to the center of excellence or the university hospitals to get the prescription every two weeks. That definitely hurt compliance in Japan in year one. People miss, the weather is bad, there are natural disasters, whatever. There are a million reasons why people are not consistent in their prescription renewal. So we were also very pleased with where we ended up in Japan. Like all drugs, we are impacted by compliance in the first year, but we expect that to change going forward. So we feel good about that.

France negotiations do take, traditionally 18 months since EMA approval. So we are due for a decision mid-next year. Until then, we are in NPP or expanded access, accruing for an eventual price, which continues to track really well. We are close on pricing with respect to Italy and Japan.

I'm sorry, with respect to Italy, thank you. Italy and Spain.

We're hoping to get going on commercial launches in those countries next year.

Roger Song
Analyst, Jefferies

Okay.

Krish Krishnan
CEO, Krystal Biotech

That said, pricing negotiations are still ongoing and things can happen, but we think if everything's pointed in the right direction, we should launch. We feel really good about the ROW. A lot of patients in these countries in ROW are genetically tested.

We are excited about the ROW business over the next two to three years.

And expect it to be a bigger factor of the overall VYJUVEK launch more than U.S. Yeah.

Roger Song
Analyst, Jefferies

Excellent. Okay. You just validated that, the comment I have earlier. So in terms of the trajectory, at the whole, ex-U.S., and the ROW, do you think it will track well with the U.S. launch? Because which I think it's kind of the best launch, within two years, 60% penetration rate.

Krish Krishnan
CEO, Krystal Biotech

Yeah. U.S. tends to be front-loaded and then kind of flattening out type launch. We expect in general, Europe and Japan to be much more linearly pointed sloping upwards. That has to do with capacity constraints at hospitals. It has to do with some of the other nuances in different countries where there's concentration in a couple centers, but it's fragmented outside.

But we expect the slope to be like a 45-degree slope line trending upwards as opposed to have the, what U.S. did, which is a lot in the first six, nine months, and then kind of tapering out.

Roger Song
Analyst, Jefferies

Got it. Okay. That trajectory, understood. The goal is to reach the similar level, if not higher.

The trajectory is a little bit kind of linear than the U.S.

Krish Krishnan
CEO, Krystal Biotech

Yeah.

Roger Song
Analyst, Jefferies

Okay. Got it. All right. We should talk a lot about the pipeline. The key one, I think investors, Wall Street is most focused on, is the NK. We know you recently announced some of the enrollment dynamic there. Just let us know, give us a little bit more detail how you think about the patient enrollment, the criteria, the screening rate because of the stringent kind of criteria. I think that can help the probability of a success, but on the other side is maybe slow a little bit the enrollment. How should we think about the dynamic there? Suma.

Suma Krishnan
President of Research and Development, Krystal Biotech

I mean, when we started the NK program, obviously we reached out to multiple sites with feasibility. Everybody was super excited because there are a lot of patients. That's why I think we got, based on what the feedback and the number of patients these sites were projecting, we gave a very aggressive timeline that we can finish enrolling. But in reality, when we started getting into, getting these sites up and running and enrolling patients, we ran into some challenges because obviously there is already an approved product. Ours is a placebo-controlled study, so there's a push for physicians to put them on the approved drug, and they don't want to be in a placebo. Besides that, obviously because we have a lot of other benefits, it's once a day versus six times a day, ease of application, the administration convenience.

But also we have very strict, stringent criteria. What we found is, yes, these sites have a lot of patients, but these patients can have lesions that are not persistent.

So even though the site says, "Yes, this is a patient that has persistent lesion." So where we found that out in our inclusion/exclusion criteria, because we are very stringent with our inclusion criteria. We've gotten really stringent to make sure that the lesion, when they're screened at baseline and when they come back for the second lesion between the two windows, either the lesion size increases in size or it stays the same. But if it's any trend of decreasing, then we don't let these patients enroll into the study.

Because we truly believe there is our drug, we have seen in animal studies, and we've seen that we can deliver NK, sustained delivery, and we know if, I mean, the drug effect will work. So we want to make sure we get the right persistent because there is a placebo-controlled study.

As you know, we don't want the placebo arm going up and affecting the study. That's very important to us.

We want to make sure we get the right patients. We have quite a few. Our challenging was we ran into screen failing a lot of patients. But I think now we understand better, so we have increased our number of sites. We have gone outside the U.S. where OXERVATE is not available, like in Europe and Eastern European countries. Also, we have really figured out strategies of how to get these patients. So I think we are seeing that. We are seeing outcome of those efforts pan out. Hopefully now because of what we see, we want to be conservative and say, be projected by end of the next year, we will have the enrollment complete.

Roger Song
Analyst, Jefferies

Have the data. Yeah. Got it. Then the OXERVATE is the current drug, which is sell pretty good. But I think a lot of benefit your 801 can add.

Suma Krishnan
President of Research and Development, Krystal Biotech

Correct.

Roger Song
Analyst, Jefferies

You think when you study this trial and then eventually it can get approval, it will become a first-line treatment or the second-line treatment? What is the feedback you are getting? Set aside the trial enrollment.

Suma Krishnan
President of Research and Development, Krystal Biotech

Yeah

Roger Song
Analyst, Jefferies

On the commercial setting, how you think about the 801KB can be used?

Suma Krishnan
President of Research and Development, Krystal Biotech

Obviously, patients would prefer once a day versus six times a day. From an administration, obviously, this is going to be just like VYJUVEK, so it's the same. You can deliver it to the patient's home, the whole eight weeks dose. They can put it in the refrigerator and drop it once a day. From a convenient perspective, six times, once a day. We also, because of the delivery of the pharmacokinetics of our vector, we see sustained expression of NK. Because in NK, very common in NK is a very short half-life. That's why they need to put it six times. It's like in an hour or so, it's all gone. We believe that with the patients at night, when they take their last dose, the exposure is compromised.

I think with our ability to continue expression once a day, I think once a day is pretty good. We'll see sustained release. We feel hopefully we'll see a good benefit from that.

Roger Song
Analyst, Jefferies

Excellent.

Krish Krishnan
CEO, Krystal Biotech

We expect it to be first line.

Roger Song
Analyst, Jefferies

You have all the benefit with the data to support, and then it will be used as the first line.

Suma Krishnan
President of Research and Development, Krystal Biotech

Correct. Same convenience. It's going to be administered at the patient's home by the patient.

Roger Song
Analyst, Jefferies

Yeah. Okay.

Suma Krishnan
President of Research and Development, Krystal Biotech

Stored in the patient's home.

Roger Song
Analyst, Jefferies

Got it. This pipeline is the potentially first, one of the eye ophthalmology, the franchise. You do have an ocular complication of the DEB. I think the data potentially can read out before the NK. How much read-through we should detect from there? In terms of the vector, safety, and potentially some efficacy.

Suma Krishnan
President of Research and Development, Krystal Biotech

Safety you can because it's the same vector, but it's apples and oranges because that's a patient-reported outcome. Very different for a DEB. Again, there is no ophthalmologist looking at. There's no that kind of outcome. Whereas in case of NK, it's very similar to the skin VYJUVEK wounds, where you have a wound at baseline. You have to identify the size of the lesion by using the staining and photography. It's very, very validated and accurate way of measuring it. You measure it at baseline, and then you measure it at end of treatment to show complete healing. I would look at NK more like the skin VYJUVEK.

Roger Song
Analyst, Jefferies

Okay.

Suma Krishnan
President of Research and Development, Krystal Biotech

Whereas with the eye, it's more symptomatic. The patients, if you look at what we're looking is that, do you have lesions? Can you open your eyes? Is there pain in your eye? Very patient-reported outcome, very different. Whereas this is a very investigator-defined endpoint. I would consider NK very similar to VYJUVEK.

But the skin-

Krish Krishnan
CEO, Krystal Biotech

I would say, look, on NK, it's a nerve damage type, even from a symptomatic perspective, right? Whereas this is more of a corneal damage through lesions. Even from a mechanism of action, one is a. It's not exactly-

Suma Krishnan
President of Research and Development, Krystal Biotech

I'll just correct. It's just not corneal. It's not corneal alone because you have eyelids. It's like surrounding the eyes. It's not purely corneal.

Krish Krishnan
CEO, Krystal Biotech

Lesion.

Suma Krishnan
President of Research and Development, Krystal Biotech

It's not corneal. It's more events, like they get blistering on the eyelids, on the top of the eye, just skin. So it's very different.

It's not complete cornea.

Roger Song
Analyst, Jefferies

Got it.

Suma Krishnan
President of Research and Development, Krystal Biotech

involvement. There is much beyond cornea.

Roger Song
Analyst, Jefferies

Got it. Okay. Great. We have two minutes left. We have a couple other pipeline, maybe just a very high level. You have a CF, and then the Hailey-Hailey, AATD, and then the cancer. All of those pipeline will potentially read out in the coming year. Which one you may be more excited than the other ones, and then we can-

Suma Krishnan
President of Research and Development, Krystal Biotech

I mean, I am excited about all of them.

Roger Song
Analyst, Jefferies

Yeah, I know.

Suma Krishnan
President of Research and Development, Krystal Biotech

CF is exciting because again, unmet medical need for these patients, and we are enrolling patients, so we will have read out middle of next year. It is super exciting because we see these patients, they are really There is nothing. Even we see patients on modulators that is not completely working for them.

It is good to see there is a good market for that, and we are very excited about the readout now that the CF Foundation and TDN is also excited. We have met with the FDA. I think that could be up and coming.

Krish Krishnan
CEO, Krystal Biotech

I will say, look, we did read out Gorlin last month.

We are coming up to read out Hailey-Hailey.

Suma Krishnan
President of Research and Development, Krystal Biotech

Hailey-Hailey.

Roger Song
Analyst, Jefferies

Yes.

Krish Krishnan
CEO, Krystal Biotech

in December. So we feel our skin franchise is getting primed up really well on those two, besides the ones that are coming up next.

Roger Song
Analyst, Jefferies

Okay. Awesome. All right. Just the last 30 seconds. Cash position, how Krystal is funded, and then all the commercial and then pipeline.

Krish Krishnan
CEO, Krystal Biotech

No, cash position is strong.

We continue with positive EPS. I think we have more than enough for all our pipeline, and we've studied that to core, which is what gave us the strength to introduce a share buyback over a two-year. I think the VYJUVEK revenue will continue to support the company really well globally. So yeah, I mean, fingers crossed, but cash, not an issue at the moment.

Roger Song
Analyst, Jefferies

Awesome. All right. Thank you, everyone.

Suma Krishnan
President of Research and Development, Krystal Biotech

Thank you.

Krish Krishnan
CEO, Krystal Biotech

Thank you.

Roger Song
Analyst, Jefferies

Thanks you .

Suma Krishnan
President of Research and Development, Krystal Biotech

Thank you so much.

Krish Krishnan
CEO, Krystal Biotech

Take care.